MIODx Aims to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy Response

Posted by on April 18, 2018 7:00 pm
Tags:
Categories: Google Articles

Source: MIODx Aims to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy Response

SAN FRANCISCO (GenomeWeb) – MIODx is developing immune repertoire sequencing-based tests to predict whether patients will have a favorable response to immunotherapy and whether they will have adverse immune reactions as a result of the therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.

Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Published at Wed, 18 Apr 2018 18:28:17 +0000

Leave a Reply

< Immunotherapy Today home